Clinical trial · Observational
A Multicentre, Retrospective Study to Evaluate the Outcome of HSCT Mismatch Unrelated Donors
Study to Evaluate the Outcome of HSCT Mismatch Unrelated Donors
NCT04598789CI-TRIAL-00055242completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary endpoint of the study was the acute GvHD incidence, the secondary endpoints were chronic GvHD incidence, overall survival (OS), transplant related mortality (TRM) incidence, relapse incidence (RI) and neutrophil and platelets engraftment after GvHD prophylaxis with ATG-CSA-MTX or PTCy-MMF-FK506
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia, Myeloid | Myeloid Leukemia | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| no intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- acute GvHD incidence
- timeFrame
- 2012-2017
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * children and adults) * HSCT from a one-antigen mismatch unrelated donors * Treated at the Centro Trapianti Metropolitano di Torino between 2012 to 2017 Exclusion Criteria: none
References
Publications (1)
- DERIVEDBerger M, Barone M, Spadea M, Saglio F, Pessolano R, Fagioli F. HSCT with mismatched unrelated donors: Bone marrow versus peripheral blood stem cells sources in pediatric patients. Pediatr Transplant. 2022 Jun;26(4):e14233. doi: 10.1111/petr.14233. Epub 2022 Jan 28. PMID 35092128